Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CD40 | P25942 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
| ▸ | PLK1 | P53350 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17844881 | 0.93 | TSHR (0.35) | TSHRRECQLCD40KDM4ELMNA | |
| SCHEMBL15592334 | 0.91 | RECQL (0.41) | TSHRRECQLCD40SLC6A5KDM4A | |
| SCHEMBL15592308 | 0.87 | SLC6A5 (0.42) | TSHRRECQLCD40SLC6A5TLR2 | |
| SCHEMBL19468573 | 0.83 | TDP1 (0.40) | TSHRPLK1 | |
| SCHEMBL13399596 | 0.82 | CNR1 (0.39) | TSHRRECQL | |
| SCHEMBL20099258 | 0.82 | SLC6A5 (0.52) | SLC6A5TLR2 | |
| SCHEMBL21652343 | 0.82 | TDP1 (0.39) | TSHRPLK1 | |
| SCHEMBL23898968 | 0.82 | CD40 (0.46) | TSHRCD40SLC6A5KDM4AHIF1A | |
| SCHEMBL20723688 | 0.82 | CD40 (0.39) | TSHRRECQLCD40SLC6A5KDM4E | |
| SCHEMBL20224789 | 0.82 | KDM4E (0.36) | TSHRRECQLKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | TSHR 413/4885RECQL 1015/4885CD40 1407/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | TSHR 413/4885RECQL 1015/4885CD40 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.